Ocular Therapeutix, Inc. (OCUL) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.25: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.8/10 and A.R:R 15.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Ocular Therapeutix is an integrated biopharmaceutical company commercializing DEXTENZA (FDA-approved intracanalicular insert for ocular inflammation) and advancing AXPAXLI, an axitinib intravitreal hydrogel in Phase 3 registrational trials for wet AMD (SOL program) and diabetic... Read more
Sell if holding. Engine safety override at $9.25: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.8/10 and A.R:R 15.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 3.8/10, high confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Ocular Therapeutix, Inc.
Latest news
- Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Sessi — benzinga May 11, 2026 negative
- RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target — benzinga May 6, 2026 positive
- Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral
- Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate — benzinga May 5, 2026 negative
- Ocular Therapeutix Enrolls First Patient In SOL-X Long-term Extension Trial For Axpaxli (Also Known As OTX-TKI) For Wet — benzinga Apr 29, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineAXPAXLI10-K Item 1: 'AXPAXLI...is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration...which we refer to as the SOL program. AXPAXLI is currently also being evaluated in a Phase 3 registrational program for diabetic retinal disease...which we refer to as the HELIOS program.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.25: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.8/10 and A.R:R 15.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $8.67. Score 3.8/10, high confidence.
Take-profit target: $22.62 (+146.9% upside). Prior stop was $8.67. Stop-loss: $8.67.
Concentration risk — Pipeline: AXPAXLI; Quality below floor (1.8 < 4.0).
Ocular Therapeutix, Inc. trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 5.4/10. Verdict: Sell.
18 analysts cover OCUL with a consensus score of 4.3/5. Average price target: $26.
What does Ocular Therapeutix, Inc. do?Ocular Therapeutix is an integrated biopharmaceutical company commercializing DEXTENZA (FDA-approved intracanalicular...
Ocular Therapeutix is an integrated biopharmaceutical company commercializing DEXTENZA (FDA-approved intracanalicular insert for ocular inflammation) and advancing AXPAXLI, an axitinib intravitreal hydrogel in Phase 3 registrational trials for wet AMD (SOL program) and diabetic retinal disease (HELIOS program). As of December 31, 2025, it had $737.1 million in cash and $82.5 million in outstanding debt.